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Longitudinal membrane function in functionally anuric patients
treated with APD: Data from EAPOS on the effects of glucose
and icodextrin prescription.
Background: Peritoneal dialysis is associated with changes
in membrane function that can lead eventually to ultrafiltra-
tion (UF) failure. Factors driving these changes are thought to
include hypertonic glucose exposure, but previously reported
associations are confounded by the presence of residual renal
function.
Methods: Longitudinal membrane function (solute trans-
port and UF capacity) were measured annually in a prospec-
tive cohort of 177 functionally anuric patients as part of the
European Automated Peritoneal Dialysis Outcomes Study
(EAPOS). Subgroup analysis was performed according to glu-
cose exposure and icodextrin use at baseline.
Results: The whole cohort experienced an increase in solute
transport and reduction in UF capacity at 12 and 24 months
that could not be explained by informative censoring. These
changes were accelerated and more severe in patients using
either 2.27% or 3.86% glucose, or those not using icodextrin
at baseline. These differences could not be explained by age,
comorbidity score, previous time spent on renal replacement,
differential dropout from the study, peritonitis rates, or, by defi-
nition, residual renal function. Patients using icodextrin at base-
line had worse membrane function and were more likely to be
diabetic. There was an association between membrane function
changes and achieved 24-hour ultrafiltration over the 2-year
study period.
Conclusion: Anuric automated peritoneal dialysis (APD) pa-
tients experience significant detrimental changes in membrane
function over a relatively short time period. Glucose appears
to enhance these changes independent of residual renal func-
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tion. Icodextrin use in these circumstances is associated with
less deterioration in membrane function.
Long-term use of the peritoneal membrane is associ-
ated with changes in function that can ultimately lead
to ultrafiltration failure [1, 2]. As a cause of treatment
failure, this increases with time on therapy, and is as-
sociated with increased rates of small solute transport,
reduced ultrafiltration capacity, and higher rates of peri-
toneal fluid absorption [3, 4]. The reduction in ultrafil-
tration capacity is a consequence of two processes: first,
the increase in solute transport, usually defined by the
dialysate:plasma ratio of creatinine at four hours, which
will result in more rapid glucose absorption, resulting in
loss of osmotic gradient. Second, there can be a reduc-
tion in the osmotic conductance of the membrane, re-
sulting in less ultrafiltration for a given glucose gradient
that is acquired with time on treatment [4, 5]. The main
causes of the changes with time on treatment are thought
to be repeated episodes of inflammation associated with
peritonitis and long-term exposure to bioincompatible
dialysate fluid [6, 7]. In particular, hypertonic glucose so-
lutions are implicated due to their hypertonicity, direct
effects of glucose toxicity, or associated levels of glucose
degradation products (GDPs). Circumstantial evidence
supports the role of dialysate glucose exposure in mem-
brane damage, both in morphologic studies of the mem-
brane [8] and longitudinal studies of function [5, 9], but
to date these analyses are confounded by the presence of
residual renal function. Because loss of function neces-
sitates the greater use of hypertonic glucose, associated
changes in membrane function might reflect the effect of
worsening uremia.
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The European Automated Peritoneal Dialysis Out-
comes Study (EAPOS) was undertaken in order to
establish the efficacy of this treatment modality in func-
tionally anuric patients treated according to previously
agreed targets for anemia, several biochemical variables,
small solute clearance, and daily ultrafiltration [10, 11].
It demonstrated that good clinical outcomes are possible,
and that the most important predictors of survival are age,
comorbidity (especially diabetes), and severe malnutri-
tion. In addition, patients who were below the ultrafiltra-
tion target at the start of the study (>750 mL/day) proved
difficult to get above target throughout the study period,
and had a significantly increased mortality. The cause of
this excess mortality in not known, but at baseline these
individuals were distinguished by their relatively poor ul-
trafiltration capacity despite equivalent solute transport.
A secondary objective of EAPOS was to examine lon-
gitudinal changes in membrane function. This was in part
because there is a relative paucity of such information in
anuric APD patients in whom exposure to dialysate fluid
is very different to continuous ambulatory peritoneal
dialysis (CAPD) patients, but also to examine the effects
of dialysis prescription on any possible changes without
the confounding effect of residual renal function. In ad-
dition, the relatively high use of icodextrin in this study
was of potential interest.
METHODS
Study design
The design and analysis of primary end points (patient
and technique survival) of EAPOS are described in de-
tail elsewhere [10, 11]. Briefly, it was a prospective study
of functionally anuric patients (urine volume <100 mL
and/or creatinine clearance <1 mL/min/1.73m2) treated
with APD undertaken in 28 centers in 14 European coun-
tries. One hundred seventy-seven of 204 screened pa-
tients were enrolled and followed for two years, or until
they stopped peritoneal dialysis. Clinicians were asked to
optimize treatment to predefined standards during the
first six months, including a solute clearance target of
≥60l/week/1.73m2, and a daily ultrafiltration volume of
≥750 mL. Clinicians had access to icodextrin, used ac-
cording to clinical discretion, and standard, pH 5.5, 40
mmol lactate-buffered glucose solutions.
A predefined, secondary end point to the study was
peritoneal membrane function, specifically solute trans-
port and ultrafiltration capacity, measured at enrollment
and again at 12 and 24 months. Episodes of peritoni-
tis were recorded, as was the use of icodextrin, and the
number, volume, and concentration of glucose exchanges.
This enables calculation of the average concentration of
glucose exposure.
Peritoneal membrane function, solute clearances,
comorbidity scoring, and data management
Peritoneal solute transport and ultrafiltration capac-
ity was determined from a standard peritoneal equilibra-
tion test, as described previously [12]. Weekly creatinine
clearance was calculated from creatinine concentration
in plasma, urine, and dialysate, 24-hour urine volume,
and 24-hour dialysate volume as described. Residual re-
nal function, when present, was measured as mean of
urea and creatinine clearances. Daily ultrafiltration was
calculated as the difference between the volume of total
dialysate infused (including both night and daytime fluid)
and the volume drained over 24 hours for the same pe-
riod as the solute collection. Comorbidities were counted
for each patient to enable calculation of the Stoke co-
morbidity score [13]. Data management was centralized;
peritoneal, urine, and dialysate concentrations of crea-
tinine and all other blood tests were measured in each
local laboratory, and results of these and all other demo-
graphic data were collated in the central EAPOS office
(Baxter Healthcare, Brussels, Belgium), where the PET
results and creatinine clearances were calculated.
Statistical analysis
All data are expressed as mean values ± SD, with
the exception of the paired plots of longitudinal mem-
brane function that utilize standard errors. Patients were
divided into subgroups according to their dialysis pre-
scription at enrollment. Between-group comparisons at
baseline and each time point of the study (e.g., low vs.
high glucose exposure, icodextrin use vs. non-use) were
made using unpaired t tests or Mann-Whitney for non-
parametric data. Longitudinal within-group changes in
membrane function were analyzed using paired t tests.
Achieved daily ultrafiltration was nonparametrically dis-
tributed so the probability of an increase or decrease over
the study period was evaluated using the Wilcoxen signed
rank test.
RESULTS
The baseline characteristics of the 177 patients enrolled
into EAPOS were as described in detail previously [10].
Briefly, 57% were men, median age was 54 (range 21–91),
and 80% were Caucasian, 12% Indo-Asian. The median
time on renal replacement was 38 months, and 36% had
previously been treated with hemodialysis. Fifteen per-
cent were diabetic, 42% had cardiovascular disease, and
solute transport characteristics were relatively high at in-
clusion: 44 (26%) had low average transport, 80 (46%)
high average, and 49 (28%) high transport characteristics
as defined by Twardowski [12]. The ultrafiltration capac-
ity for these categories was 412 (± 239), 313 (± 271),
and 266 (± 260) mL, respectively. For purposes of this
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Table 1. Demographic characteristics according to baseline glucose concentration and icodextrin use
Low glucose High glucose Icodextrin No icodextrin
group group group group
Number 43 134 82 95
Age years 55.3 (18.7) 50.9 (15) 50.7 (16.5) 53.2 (15.6)
Sex ratio M:F 57:43 59:41 58:42 56:44
Body surface area m2 1.67 (0.2) 1.78 (0.2) 1.77 (0.2) 1.75 (0.2)
Diabetic% 12% 16% 20% a 11%
Cumulative comorbid score 0.91 (1.0) 0.8 (1.0) 0.96 (1.1) 0.71 (0.9)
Baseline daily achieved ultrafiltration mL 1218 (678) 1200 (617) 1267 (659) 1029 (585)
Baseline daily achieved creatinine clearance L/wk/1.73m2 65.3 (15.9) 64.5 (15) 65.1 (16.1) 64.4 (14.5)
Average number of previous renal transplants 0.3 (0.5) 0.39 (0.6) 0.43 (0.6) 0.32 (0.6)
Median months on renal replacement 38.1 42.5 44.8 37.7
aP = 0.05, one-tailed nonparametric test compared with patients not using icodextrin.
Table 2. Numbers of patients, dialysate glucose exposure, dialysate volume, and peritonitis rate at six monthly intervals during the study
Baseline 6 months 12 months 18 months 24 months
Low glucose group N 43 34 (79%)d 24 (56%) 18 (41%) 13 (30%)
Mean percentage glucose exposure 1.36 (0.06)a,c 1.6 (0.42)a 1.54 (0.27)a 1.65 (0.49)a 1.53 (0.23)a
Mean 24-hour dialysate volume L 15.5 (3.9) 16.6 (3.7) 16.4 (3.4) 17.5 (3.5) 16.9 (3.4)
Peritonitis mean rate for 6 months 0.35 (0.5) 0.18 (0.4) 0.22 (0.4) 0.50 (0.6)
High glucose group N 134 103 (77%) 77 (57%) 57 (42%) 44 (33%)
Mean percentage glucose exposure 2.1 (0.45) 2.1 (0.45) 2.1 (0.48) 2.2 (0.5) 2.2 (0.51)
Mean 24-hour dialysate volume L 15.7 (3.3) 16.1 (3.5) 16.5 (3.2) 16.8 (3.3) 16.1 (3.9)
Peritonitis mean rate for 6 months 0.25 (0.4) 0.26 (0.4) 0.29 (0.5) 0.30 (0.6)
Icodextrin group N 82 59 (72%) 48 (59%) 36 (43%) 27 (33%)
Mean percentage glucose exposure 2.1 (0.58) 2.1 (0.55) 2.1 (0.57) 2.1 (0.6) 2.1 (0.61)
Mean 24-hour dialysate volume L 15.6 (3.3) 16.4 (3.6) 16.4 (3.4) 16.7 (3.4) 15.4 (4.3)
Peritonitis mean rate for 6 months 0.35 (0.6) 0.23 (0.4) 0.35 (0.8) 0.40 (0.7)
No icodextrin group N 95 78 (82%) 53 (56%) 39 (41%) 30 (31%)
Mean percentage glucose exposure 1.84 (0.41)b 1.89 (0.43) 1.93 (0.43) 2.0 (0.48) 1.91 (0.44)c
Mean 24-hour dialysate volume L 15.7 (3.6) 16.2 (3.6) 16.5 (3.1) 17.2 (3.2) 16.8 (3.2)
Peritonitis mean rate for 6 months 0.22 (0.5) 0.24 (0.5) 0.20 (0.5) 0.31 (0.6)
All patients N 177 137 (77%) 101 (57%) 75 (42%) 57 (32%)
Mean percentage glucose exposure 1.95 (0.51) 1.96 (0.49) 1.99 (0.5) 2.04 (0.54) 2.01 (0.53)
Mean 24-hour dialysate volume L 15.7 (3.5) 16.3 (3.6) 16.5 (3.2) 16.9 (3.3) 16.3 (3.8)
Peritonitis mean rate for 6 months 0.28 (0.6) 0.24 (0.5) 0.27 (0.6) 0.35 (0.6)
aAverage glucose concentration less compared to the high glucose group, P < 0.001.
bAverage glucose concentration less compared to the icodextrin group, P = 0.003.
cAverage glucose concentration increased/decreased compared to six months, paired t test, P < 0.05.
dPercentage of each group remaining in the study at each time point.
analysis, patients were divided according to their glucose
prescription and their use of icodextrin at baseline, re-
sulting in four subgroups (two pairs). Low glucose ex-
posure was defined as regimens containing 1.36% only,
used by 43 (24%) of patients, whereas 134 patients used
at least one 2.27% or 3.86% exchange. Just under half, 82
(46%) of patients were using icodextrin at baseline. These
groupings were not, however, mutually exclusive, with 19
patients combining icodextrin with 1.36% glucose only,
and 71 using ≥2.27% glucose and not using icodextrin.
The differences in baseline demography of these group-
ings are summarized in Table 1, showing that these char-
acteristics were not different, with the exception of the
proportion of diabetics according to icodextrin use.
Table 2 shows the number of patients, their average
dialysate glucose concentration, total dialysate volume,
and peritonitis rate at six monthly intervals during follow-
up in each of these categories, as well as for the whole
population. It can be seen that the proportion of pa-
tients using low versus high glucose concentration flu-
ids, and those using icodextrin as opposed to not doing
so at baseline, was similar throughout the study period.
Furthermore, the average glucose use remained lower
throughout the study in those using low glucose concen-
trations at baseline. There was a significant increase in
the mean glucose concentration in these patients during
the first six months of treatment, however, reflecting at-
tempts by clinicians to reach the ultrafiltration targets set
in the primary study design. Patients using icodextrin at
the start of the study also had a higher average glucose
concentration, but this difference disappeared with time
due to the increased use of glucose in those patients not
using icodextrin. A small number of patients commenced
icodextrin during the course of the study (N = 7), but no
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Table 3. Mean (SD) values for solute transport and UF capacity for
all patients in each subgroup and whole study population at each time
point
Baseline 12 months 24 months
Low glucose group N 42 21 (50%) 11 (26%)
Mean solute transport ratio 0.74 (0.11) 0.76 (0.08) 0.8 (0.11)c
Ultrafiltration capacity mL 309 (278) 318 (279) 276 (250)
High glucose group N 131 72 (55%) 37 (28%)
Mean solute transport ratio 0.75 (0.12) 0.8 (0.11)b 0.82 (0.1)b
Ultrafiltration capacity mL 333 (269) 293 (271) 228 (290)b
Icodextrin group N 80 44 (55%) 22 (28%)
Mean solute transport ratio 0.76 (0.11)a 0.79 (0.11) 0.78 (0.1)a,c
Ultrafiltration capacity mL 272 (302)a 277 (312) 299 (292)
No icodextrin group N 93 49 (52%) 27 (29%)
Mean solute transport ratio 0.73 (0.12) 0.83 (0.1)b 0.85 (0.1)b
Ultrafiltration capacity mL 374 (232) 318 (228)c 188 (264)b
All patients N 173 91 (53%) 48 (27%)
Mean solute transport ratio 0.75 (0.11) 0.8 (0.1)b 0.82 (0.1)b
Ultrafiltration capacity mL 327 (271) 298 (271) 239 (279)b
For paired values only, see data represented in Figures 1 through 3.
Between group analysis, different to patients not using icodextrin, aP < 0.02.
Paired analysis, changed from baseline, bP ≤ 0.006; cP ≤ 0.02.
400
350
300
250
200
150
100
UF
 c
ap
ac
ity
,
 
m
L
0.72 0.74 0.76 0.78 0.8 0.82 0.84
Solute transport
Baseline
12 months
24 months
Fig. 1 Longitudinal membrane function for the whole patient cohort.
Each data point represents the mean values (±SE) for the patients
who remained in the study for the full two years. (For longitudinal
paired statistics and mean values for all patients at each time point, see
Table 3).
patients stopped using it. There were no significant dif-
ferences between any of the groups or time periods in the
peritonitis rate throughout the study.
Table 3 (for all patients at each time point) and Figures
1 to 4 (paired data only) summarize the actual membrane
characteristics at baseline, 12, and 24 months, again for
the above subgroupings, as well as for the patient group
as a whole. It can be seen that baseline membrane func-
tion for those using icodextrin from start of the study
was different, with higher solute transport and reduced
ultrafiltration capacity when compared to those not us-
ing this product. There were no differences in membrane
function according to glucose usage at baseline. For the
patient group as a whole, there was a significant increase
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Fig. 2. Longitudinal membrane function according to baseline glucose
exposure, patients using 1.36% only (), 2.27% or 3.86% (•). As indi-
cated in Figure 1, data points represent paired mean values (±SE) for
patients remaining throughout the study that move from left to right at
baseline, 12 and 24 months. (For longitudinal paired statistics and mean
values for all patients at each time point, see Table 3).
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Fig. 3 Longitudinal membrane function according to baseline use of
icodextrin (•) or no icodextrin (). As indicated in Figure 1, data points
represent paired mean values (±SE) for patients remaining throughout
the study that move from left to right at baseline, 12 and 24 months.
(For longitudinal paired statistics and mean values for all patients at
each time point, see Table 3).
in solute transport during the course of the study that was
already apparent by one year. Ultrafiltration capacity de-
creased during the study and, as can be seen in Figure 1,
this was especially marked during the second year, where
the data points represent values for the paired data only.
When patients were divided according to their baseline
glucose concentration (Table 3, Fig. 2), both groups had
an increase in solute transport, although this was more
marked and occurred earlier in the patients using ≥2.27%
solutions. This group also had a significant fall in ultra-
filtration capacity by 24 months. Longitudinal changes in
membrane function were least apparent in the patients
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Fig. 4. Longitudinal membrane function according to whether patients
experienced no peritonitis () or one or more episodes (•). As indicated
in Figure 1, data points represent paired mean values (±SE) for patients
remaining throughout the study that move from left to right at baseline,
12 and 24 months. Significant changes longitudinal changes occur in
both groups, and appear more rapid and severe in the peritonitis group,
but between group comparisons are not statistically significant.
using icodextrin from the start of the study (Table 3,
Fig. 3). They had no changes in ultrafiltration capacity,
and a relatively small but significant increase in solute
transport, such that their mean value was less than their
comparator group at 12 months—the inverse of the situ-
ation at the beginning of the study. As might be expected
from the above, those patients with regimens that ex-
cluded icodextrin but used higher glucose concentrations
had the most marked changes in longitudinal membrane
function. Solute transport at baseline: 0.74, 24 months:
0.84, P < 0.001, and ultrafiltration capacity at baseline:
437 mL, 24 months: 196 mL, P = 0.006. In the con-
verse group (i.e., icodextrin and 1.36% glucose only),
membrane function was unaltered, solute transport at
baseline: 0.72, 24 months: 0.73, NS, and ultrafiltration
capacity at baseline: 405 mL, 24 months: 414 mL, NS,
although numbers were very small.
The influence of peritonitis rate on longitudinal mem-
brane changes was also investigated. When comparing
patients who had no peritonitis with those who had at
least one episode, it appears that the latter group had
more rapid changes in membrane function, but this was
not statistically significant (see Fig. 4).
The relationship of these four groupings to changes in
achieved daily ultrafiltration was also explored. It can be
seen from Table 4 that there was a tendency in all four
groups for the daily ultrafiltration volume to be less at the
end of the study than at baseline, in keeping with previous
analyses. This was more marked, and statistically signifi-
cant in the groups who had more detrimental changes in
membrane function.
Table 4. Proportion of patients whose net achieved daily
ultrafiltration increased or decreased between baseline and the end
of the study
Number with Number with
increasing daily decreasing daily
ultrafiltration ultrafiltration
during study during study P valuea
Low glucose group 5 (38%) 8 (62%) 0.55
High glucose group 11 (27%) 29 (73%) 0.002
Icodextrin group 9 (34%) 17 (66%) 0.10
No icodextrin group 7 (26%) 20 (74%) 0.008
aWilcoxon signed rank test.
DISCUSSION
This is the first detailed description of longitudinal
changes in membrane function occurring in functionally
anuric patients treated with automated peritoneal dial-
ysis. It is also the largest study describing longitudinal
membrane changes in patients using icodextrin. The non-
randomized nature of the study design combined with
variability in the clinician attempts to reach the prea-
greed ultrafiltration target of 750 mL per day need to
be taken into account in interpreting data. Nevertheless,
it confirms previous longitudinal studies showing that so-
lute transport increases and ultrafiltration capacity de-
creases with time on treatment [1, 5, 7, 14], and supports
the evidence that hypertonic glucose exposure acceler-
ates this process independently of residual renal function
loss. Icodextrin would appear at least to be a safe solu-
tion in these circumstances, and potentially seems to be
of benefit.
Most studies with sufficient numbers and a prospec-
tive design, thus reducing selection bias, have indicated
that peritoneal solute transport increases with time on
treatment [1, 5, 7, 14]. This is associated with a re-
duction in the peritoneal ultrafiltration capacity and an
increased risk of ultrafiltration failure with time on treat-
ment. The reason for the drop in UF capacity is in part
explained by the more rapid absorption of the glucose
during the dwell, although there is increasing evidence
that the hydraulic conductance of the membrane is also
affected due to intrinsic changes in the peritoneal mem-
brane [4, 7]. The observations of the present study support
these concepts in that increasing solute transport was as-
sociated with an expected fall in ultrafiltration capacity,
which tended to be disproportionately large, especially
in the second year of the study. In an observational study
such as this it is always important to consider that the
findings are a function of informative censoring. This is
very unlikely to be the explanation of the findings pre-
sented here because a reduction in ultrafiltration capac-
ity is more likely to lead to patient withdrawal, especially
in view of the study design that encouraged clinicians to
achieve a minimum daily ultrafiltration. Previous analy-
sis of this study showed that patients not achieving >750
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mL of daily ultrafiltration at baseline had a significantly
higher death rate, were less likely to achieve target ultra-
filtration throughout the study, and had worse peritoneal
ultrafiltration capacity (but not solute transport) at base-
line. If anything, therefore, this observational study has
underestimated the severity of membrane changes with
time because patients with the worst ultrafiltration capac-
ity will have left the study earlier.
Compared to other longitudinal studies of membrane
function, the changes observed here appeared to be more
rapid than might be anticipated. This may reflect two
things: first, the fact that most patients had been on re-
nal replacement for some time, typically more than three
years, and thus had time to acquire membrane damage.
Their average peritoneal transport was relatively high at
the start of the study and uremia itself might contribute
to changes in the peritoneal membrane. Second, APD is
a treatment associated with use of larger dialysate vol-
umes over the 24-hour period and shorter exchanges of
dialysate, resulting in more frequent changes in intraperi-
toneal pH and greater exposure to lactate, hypertonic
glucose, and GDPs.
The principle difficulty in demonstrating a link between
glucose exposure and membrane function changes in pre-
vious observational studies has been that of sorting out
cause and effect. Clearly, worse membrane function dic-
tates the use of more hypertonic glucose. Equally, if the
patient has lost residual renal function, then more ul-
trafiltration will be required. The demonstration, in ei-
ther selected [9] or unselected patients [5], that increased
use of hypertonic glucose precedes changes in membrane
function go some way toward addressing the first of these
concerns, but the increased use of glucose in these circum-
stances was due to loss in residual renal function. This still
leaves the criticism that membrane change was driven by
progressive uremia, possibly due to associated membrane
inflammation [15], rather than exposure to glucose itself,
or its harmful associates, such as GDPs. The importance
of the present study is that residual renal function is elim-
inated as a confounding factor, and patients were treated
to a common standard in terms of small solute clearance.
In comparing the groups avoiding or using hypertonic glu-
cose at the start of the study, there are no clear differences
at baseline, and the relative proportion in each group re-
mained in the study at each of the six monthly time points,
again making informative censoring an unlikely explana-
tion of the differences in membrane function that were
observed. As with previous studies, exposure to higher
concentrations of glucose appears to be associated with
accelerated changes in membrane function, although it
remains possible that some unidentified but causative se-
lection factor is associated with the use of higher glucose
concentrations at baseline in this study.
Patients using icodextrin at the start of the study had
less marked changes in longitudinal membrane function
when compared to those who were not. This difference
appears to be independent of age, treatment time, or peri-
tonitis during the study period, and occurred despite the
fact that they had worse membrane function at the be-
ginning, an observation compatible with the appropriate
clinical use of this product [16]. This group of patients was
more likely to be diabetic, again reflecting appropriate
clinical practice. There is no reason to think that diabetics
are less prone to worsening changes in membrane func-
tion. If anything, patients with multiple comorbidities,
frequently diabetic, have more marked changes in mem-
brane function [17]. In the absence of any other explana-
tion this study would suggest that icodextrin is beneficial
under these circumstances. There is some debate as to the
relative benefits of icodextrin in terms of its biocompati-
bility, although on balance its properties are favorable. It
is iso-osmolar with plasma, but has a relatively low pH of
5.1. It avoids the use of glucose, and contains reduced lev-
els of GDPs compared to conventional solutions [18, 19].
Furthermore, it possibly enhances peritoneal removal of
advanced glycation end products [20], and both in vivo
and ex vivo studies of cellular toxicity have generally been
favorable [21]. There has been concern that its use is as-
sociated with sterile or allergic peritonitis, although this
was not apparent in this study [22]. Some concerns have
been raised regarding dysplastic change in mesothelial
cells associated with lipid peroxidation in animal models
of icodextrin exposure, although the relevance of these
findings remains unclear, and have not yet been observed
in the human, where there is no intraperitoneal amylase
[23]. Bearing in mind the nonrandomized nature of this
study and, thus, the potential for unmeasured confound-
ing effects, it would appear that the use of icodextrin in
anuric APD patients is supported by these observations
of relatively preserved membrane function in addition to
other clinical indications for its use.
CONCLUSION
Finally, we were interested to see if the variable changes
in membrane function according to prescription trans-
lated into differences in achieved daily ultrafiltration.
One of the important findings of EAPOS was a modest
but highly significant fall in achieved ultrafiltration during
the course of the study that cannot be explained by in-
formative censoring, reduced use of hypertonic glucose,
or icodextrin [10]. This trend was seen in each of the sub-
groups analyzed but was proportionately more likely and
more statistically significant in either those using more hy-
pertonic glucose or not using icodextrin. It would seem,
therefore, that these changes in membrane function are
more than of simple theoretical concern; rather that they
may lead either to changes in fluid status or a need for
more strict fluid restriction in APD patients with time on
treatment. There is clearly a need for longitudinal studies
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of the newer biocompatible dialysis solutions in APD pa-
tients to establish their role in membrane preservation.
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